Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes

CAMBRIDGE, Mass., June 27, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication in Diabetes Care of positive clinical data from a Phase 2 study of volanesorsen in patients with high plasma triglyceride (TG) levels and type 2 diabetes. Results from the study showed that, in addition to reductions in plasma TG and apolipoprotein C-III (ApoC-III), a key factor in TG regulation, volanesorsen improved insulin sensitivity and glucose control. Volanesorsen is currently being evaluated in two pivotal Phase 3 studies—the APPROACH FCS study in patients with familial chylomicronemia syndrome (FCS) and the BROADEN FPL study in patients with familial partial lipodystrophy (FPL). In addition, the COMPASS study—a Phase 3 study designed to support global regulatory filings—is also ongoing.

The release as fetched from its publisher. ionis.com ↗